Hemoglobin S
EstablishedHemoglobin S is the abnormal variant causing sickle cell disease, detected via newborn screening.
Hemoglobin S causes sickle cell disease. Newborn screening catches it early so treatment can start right away. Treatment options have shifted recently — one drug was pulled from the market in 2024 for safety reasons, while a new easier-to-use hydroxyurea formula was approved the same year for very young children.
Hemoglobin S is the abnormal hemoglobin variant responsible for sickle cell disease, caused by a single point mutation in the HBB gene that makes red blood cells rigid and sickle-shaped under low-oxygen conditions.
Detection of hemoglobin S on newborn screening or hemoglobin electrophoresis confirms sickle cell trait (one copy) or sickle cell disease (two copies, or one copy plus another abnormal beta-globin variant like hemoglobin C).
Screened via newborn heel-stick using tandem mass spectrometry, HPLC, or isoelectric focusing; confirmatory testing and genetic counseling follow a positive screen, with universal (rather than ancestry-targeted) screening increasingly adopted globally.
The treatment landscape shifted meaningfully in 2024: voxelotor (approved 2019) was voluntarily withdrawn from all markets in September 2024 after data showed increased vaso-occlusive crises and fatal events outweighing benefit. Meanwhile, a new oral hydroxyurea solution (Xromi) was approved in 2024 for children as young as 6 months, and gene therapies (approved 2023) remain available for severe disease, alongside continued expansion of universal newborn screening internationally.
2024 saw both a major drug withdrawal (voxelotor) and a new approval (oral hydroxyurea solution) in this space.
- Medscape. Sickle Cell Disease (SCD) Treatment & Management.
- PMC. (2026). Newborn Screening for Hemoglobinopathies and Thalassemias: Recent Activities and Global Status.